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1. Introduction
Long QT syndrome is a rare disorder of cardiac ion channels, characterised by a prolonged
QT interval and T-wave abnormalities on electrocardiogram (ECG) and the occurrence of
the ventricular tachycardia torsade de pointes. Sodium, potassium or calcium channels present
in heart muscle may be affected, altering the regulation of electrical current in the cells [1-3].
Individuals with this condition will be predisposed to cardiac events such as arrhythmias
and polymorphic ventricular tachycardia, which may lead, if untreated, to sudden cardiac
death [2,3]. Thirteen genes are associated with the condition, and hundreds of mutations
have been identified [3-5]. Currently, more than 95% of the pathogenic mutations listed in
disease databases (Gene Connection For the Heart, http://www.fsm.it/cardmoc/; online Hu‐
man Gene Mutation Database, www.hgmd.cf.ac.uk/) are sequence variants (including point
mutations and small insertions or deletions), but the importance of whole or multi-exon de‐
letions and duplications has more recently been recognised [6] and it is now recommended
to use both sequence and dosage techniques in order to provide comprehensive analysis [3].
In New Zealand, the majority of specimens referred for Long QT syndrome diagnostic test‐
ing are retrieved after death. Postmortem specimens are often difficult to handle as they are
usually either tissue samples or severely haemolysed blood. The extracted DNA is frequent‐
ly of low quality, due to the presence of unwanted material such as short fragments pro‐
duced by degradation and chemical modifications from oxidation and hydrolysis processes
[7]. As a result, only short sequences can be reliably amplified [7]. Moreover, capillary-based
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sequencing, the gold standard first-line diagnostic test for Long QT syndrome, is very sensi‐
tive to the presence of contaminants, such as proteins, RNA and residual salt. The presence
of such contaminants leads to poor quality electropherograms for analysis, which tend to be
compromised by the presence of dye blobs, C-shoulders and a variable degree of baseline
noise (Figure 1). Although the QC requirements for array comparative genomic hybridisa‐
tion (aCGH), which can be used to detect whole exon deletion and duplication mutations,
are less stringent than those for sequencing, contamination or degradation of sample DNA
can lead to suboptimal efficiency of labelling and hybridisation. Such difficulties arising in
the practical procedure mean that the analysis of postmortem DNA can be time-consuming
and challenging, and obtaining high quality data within a reasonable timeframe can be ex‐
tremely difficult.
Figure 1. Electropherograms showing poor quality sequence data.
Long QT syndrome affects 1 in 2000 individuals [8] and contributes to 15-25% of sudden un‐
explained death in 1-40 year olds [9,10] and 10% of sudden unexplained deaths in infancy
(SIDs) [11]. As a consequence, it is an important differential diagnosis to be considered in all
cases of autopsy negative young sudden death. Molecular genetic testing is essential to
make a postmortem diagnosis, given that screening for the electrocardiogram characteristics
is no longer possible after death. Historically the turnaround time for diagnosis has been up
to six months, due to the large number of genes to be analysed and the difficulties inherent
in dealing with postmortem specimens (as detailed above). However, the demand by coro‐
ners for diagnostic laboratories to undertake more rapid analysis has been steadily increas‐
ing. A protocol tailored specifically to the treatment of postmortem specimens is necessary
to meet this demand. Within our laboratory, we have successfully developed a robust proc‐
ess for sequence and dosage analysis of postmortem samples and have achieved an excellent
turnaround time of 6-12 weeks. Here, we address the critical QC parameters that should be
considered in order to obtain high quality data for rapid, accurate analysis. The discussion
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presented below concerns both sequence analysis and dosage analysis. The former uses con‐
ventional sequencing technology, while the latter involves the simultaneous high resolution
screening of deletion and duplication mutations in multiple cardiac genes as opposed to the
more conventional multiplex ligation dependent probe amplification (MLPA) technique,
which many diagnostic laboratories still use [6].
2. Materials and methods
2.1. Sequencing
2.1.1. Primer design
We have used two approaches to design primers flanking each of the coding exons of the
genes KCNQ1 (LQT1), KCNH2 (LQT2), SCN5A (LQT3), KCNE1 (LQT5), KCNE2 (LQT6), and
KCNJ2 (LQT7), including at least 50 base pairs of the flanking intronic regions. The first used
the primer design program called PrimerQuest (Integrated DNA Technologies Inc; http://
www.idtdna.com/Scitools/Applications/Primerquest/Advanced.aspx). This program allows
the region in a sequence file to be specified, against which primers are designed to flank the
targeted region. The designed primers for each exon are then checked in silico for annealing
characteristics using the Macintosh-based program, Amplify. Finally, all primers were
checked for single nucleotide polymorphisms (SNPs) using the software tool available from
the National Genetic Reference Laboratory, Manchester (http://ngrl.man.ac.uk/SNPCheck/
SNPCheck.html). This bioinformatics program uses the current National Center for Biotech‐
nology Information (NCBI) build of the human genome and the current release of the Single
Nucleotide Polymorphism database (dbSNP) to identify the position in the sequence where
the primers bind and to detect any known SNPs at these sites
Following the above approach, we developed an alternate design protocol [12,13]. Each
mRNA sequence of interest was identified through the public UCSC genome browser page
http://genome.ucsc.edu. This website provides a direct link to ExonPrimer for the design of
primers specific to the mRNA sequence. ExonPrimer uses exon position information provid‐
ed by the UCSC genome browser in combination with the primer design tool Primer3 to cre‐
ate primer pairs according to set parameters, while avoiding pairing to homologous regions
within the genome. Exon and amplicon size are provided and multiple alternative primer
sets are given. Following primer design, all primers were checked for single nucleotide poly‐
morphisms (SNPs), as described above. Following a negative SNP check the primer sequen‐
ces were evaluated using the UCSC genome browser to confirm the identification of single
amplicons. Each primer was then tailed with an M13 sequence and manufactured by Inte‐
grated DNA Technologies Inc or Life Technologies. In this way, primers are designed to al‐
low amplification of all exons of interest and the corresponding splice sites using a single set
of PCR conditions such that PCR (and subsequent sequencing) can be performed under
identical conditions within a 96-well PCR plate.




Genomic DNA (gDNA) was extracted from peripheral blood leucocytes (EDTA blood sam‐
ples) using the Gentra Puregene DNA Extraction kit (Qiagen), according to the manufactur‐
er's instructions.
A standard phenol/chloroform protease protocol was used to extract gDNA from postmor‐
tem tissue specimens. A small section (2mm x 2mm x 4mm) is usually cut from frozen tissue
and diced as finely as possible using a scalpel blade. The tissue is placed into a 1.5ml micro‐
centrifuge tube with 450µl of 1x TES Buffer (1M NaCl, 0.5M Tris-HCl, 10mM EDTA), 60µl of
20µg/µl Proteinase K (Roche) and 10µl of 10% SDS, and incubated overnight with vigorous
shaking. Following digestion, an equal volume of phenol is added and the sample is vor‐
texed vigorously. Once homogenous, the sample is centrifuged to separate the layers and
the top aqueous layer is removed and transferred to a fresh 1.5ml centrifuge tube. An equal
volume of chloroform is then added to the aqueous layer. This is vortexed, centrifuged, and
the aqueous (top) layer again transferred to a fresh tube. A 2x volume of 100% ethanol is
added to the aqueous layer to precipitate the DNA, followed by centrifugation at 13,000rpm
and the supernatant is removed. The pellet is then washed with 70% ethanol and re-centri‐
fuged for 2 minutes at 13,000rpm. The supernatant is again removed, and the pellet air dried
prior to re-suspension in TE buffer (10mM Tris-HCl, 1mM EDTA, pH 7.0-8.0).
The quality and quantity of extracted gDNA is measured using a NanoDrop ND-1000 Spec‐
trophotometer.
2.1.3. PCR
PCR amplification is performed in a final 25µl reaction volume with the following reagents:
Faststart buffer (Roche Applied Science), 2mM MgCl2 (Roche Applied Science), M13-tailed
forward and reverse primers at 0.8µM each (synthesised by Integrated DNA Technologies
Inc), 0.4mM dNTPs (GE Healthcare Ltd), 1 unit Faststart Taq DNA polymerase (Roche Ap‐
plied Science) and 5µl GC-rich solution (Roche Applied Science). 50ng of gDNA is included
in each reaction. PCR amplification is carried out with the following conditions: denatura‐
tion at 95°C for 5 minutes, followed by 35 cycles of 94°C for 45 seconds, 60°C for 30 seconds
and 72°C for 30 seconds, with a final extension of 72°C for 10 minutes.
2.1.4. Sequencing (Figure 2)
5µL of each PCR is cleaned with ExoSAP-IT (Affymetrix, USB) prior to bidirectional DNA
sequencing using M13 forward and reverse primers and Big-Dye Terminator v3.0 (Applied
Biosystems Ltd). 20µl of each sequenced product is manually purified using the CleanSEQ
Sequencing Purification System (Agencourt Bioscience). Four different drying times prior to
elution (20 minutes, 24 hours, four days and seven days) were assessed to establish an opti‐
mal drying time for generating high quality sequencing data. 15µL of purified product was
then subjected to capillary electrophoresis using the Applied Biosystems model 3130xl Ge‐
netic Analyzer.
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The analysis of sequence traces is performed using Variant Reporter v1.0 (Applied Biosys‐
tems). Variant Reporter uses advanced algorithms and quality metrics to automate the de‐
tection of variants and to streamline the analysis process.
Figure 2. Flowchart of the sequencing method used in our laboratory.
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2.2. Array comparative genomic hybridization (aCGH)
A Roche NimbleGen 12x135K Custom CGH Array was used for dosage analysis. This be‐
spoke CGH array has been designed to screen for dosage changes within the genes responsi‐
ble for LQT1-12 (KCNQ1, KCNH2, SCN5A, ANK2, KCNE1, KCNE2, KCNJ2, CACNA1C,
CAV3, SCN4B, AKAP9, and SNTA1), the LQT-associated genes GPD1L, KCNE3, SCN1B,
SCN3B, CACNB2, and the CPVT1 (RYR2) and CPVT2 (CASQ2) genes.
Two hundred and fifty nanograms of gDNA are processed according to the manufacturer’s
instructions (NimbleGen Array User’s Guide: CGH and CNV Arrays v8.0; http://
www.nimblegen.com). In brief, extracted gDNA from samples and Promega controls are de‐
natured in the presence of a Cy3- (test) or Cy5- (control) labelled random primers and incu‐
bated with the Klenow fragment of DNA polymerase, together with dNTPs (5mM of each
dNTP), at 37ºC for 2 hours. The reaction is terminated by the addition of 21.5µL of 0.5M ED‐
TA, prior to isopropanol precipitation and ethanol washing. Following quantification, the
test and sex-matched control samples are combined in equimolar amounts and applied to
one of the twelve arrays on a microarray slide. Hybridisation is carried out in a Roche Nim‐
bleGen Hybridisation Chamber for a period of 48 hours. Slides are washed and scanned us‐
ing a NimbleGen MS 200 Microarray Scanner. Array image files (.tif) produced by the MS
200 Data Collection Software are imported into DEVA v1.2.1 (Roche NimbleGen Inc) for
analysis. Each genomic region exhibiting a copy number change within one of the LQT
genes of interest were examined using the UCSC genome browser (http://genome.ucsc.edu/)
to determine the location and significance of the change.
3. Results
In order to overcome the historical difficulties faced when performing Long QT syndrome
testing using postmortem specimens and meet the demand by coroners for rapid results, we
addressed the following parameters:
3.1. DNA purity
Since poor quality gDNA leads to suboptimal PCR amplification affecting downstream ap‐
plications, the purity of gDNA is an important criterion for success in generating high quali‐
ty sequencing data [14,15]. A NanoDrop ND-1000 spectrophotometer was used to measure
the quality and quantity of the extracted gDNA. The ratio of absorbance at 260nm and
280nm (A260/280 ratio) is used to assess the purity of gDNA, which should be in the range
of 1.8 to 2.0 to be accepted as pure gDNA. The ratio of absorbance at 260nm and 230nm
(A260/230 ratio) is used as a secondary measure of nucleic acid purity, and for pure gDNA
should be in the range of 2.0-2.2 [16]. Postmortem gDNA isolated using a standard phenol/
chloroform protease protocol may contain residual phenol, chloroform or ethanol. These
contaminants inhibit the activity of DNA polymerase in downstream applications (Figures
3-5) [14], so the purity of the gDNA must be strictly monitored. If a suboptimal A260/280 or
A260/230 ratio indicates that the gDNA is of low quality, a secondary cleanup process
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should be considered. In our laboratory, we perform this cleanup using another phenol ex‐
traction and ethanol precipitation to further purify the gDNA sample [17].
Figure 3. Agarose gel image of PCR amplification from an impure DNA with an acceptable A260/280 ratio (1.88) but an
acceptable A260/230 ratio (2.5) . NOTE: very few exons amplified effectively and strong primer dimers are visible.
Figure 4. Agarose gel image of PCR products amplified from the same DNA sample after purification. NOTE: success‐
ful amplification and significantly reduced primer dimers.
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Figure 5. Electropherogram generated from an impure DNA sample with an acceptable A260/280 ratio (1.95) but an un‐
acceptable A260/230 ratio (0.95). NOTE: significant baseline noise and data unable to be analysed.
3.2. Amount of DNA template used in a sequencing reaction
The extent of dilution of the cleaned PCR product prior to sequencing determines the
amount of DNA template used in the sequencing reaction, which can affect the data quality
for analysis [15]. The presence of excessive DNA template in a sequencing reaction will lead
to rapidly progressive signal loss on the electropherogram (Figure 6), while using insuffi‐
cient DNA template in a sequencing reaction will result in weak signal strength and a loss of
peak shape (Figure 7), causing difficulties in basecalling and accurate analysis [15]. In order
to obtain high quality data with good signal strength, the amplified product should be dilut‐
ed in ddH20 to as close as possible to 2.5ng per 100bp.
Figure 6. Electropherogram begins with strong high peaks, which fade rapidly.
Figure 7. Electropherogram with increased background noise and loss of sharp peak shape.
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3.3. CleanSEQ treatment of sequencing reactions
The sequenced product is purified using an Agencourt CleanSEQ system, which uses SPRI
(Solid Phase Reversible Immobilization) magnetic bead-based technology. According to the
manufacturer’s recommendation, the sequencing product should be cleaned using undilut‐
ed CleanSEQ reagent, but in our experience, postmortem DNA samples should be cleaned
using CleanSEQ reagent diluted 1:2 in ddH20 (figures 8,9).
Figure 8. Electropherogram obtained from sequencing product cleaned with 10µl of undiluted CleanSEQ reagent: se‐
rious baseline noise and incorrect basecalling.
Figure  9.  Electropherogram  obtained  from  sequencing  product  cleaned  using  diluted  CleanSEQ  reagent:  good
quality trace.
3.4. Drying of DNA-bound beads prior to elution
The length of drying time following ethanol washing and prior to elution of the sequencing
product from the CleanSEQ beads is one of the critical parameters for obtaining high quality
sequence data. We assessed 4 different drying periods: 20 minutes, 24 hours, four days and
seven days.
A drying time of 20 minutes, as recommended by the manufacturer, is frequently associated
with the presence of large ‘dye blobs’, most probably as a result of residual ethanol in the
eluted product (Figure 10); this problem resolves if drying time is extended to 24 hours (Fig‐
ure 11). However, variable baseline noise on the electropherogram will be evident if the dry‐
ing time exceeds four days (Figure 12); further increased background noise and loss of
resolution occur when the drying time exceeds seven days (Figure 13).
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Figure 10. Electropherogram of purified products dried for 20 minutes prior to elution; presence of large dye blob.
Figure 11. Electropherogram of purified products dried for 24 hours prior to elution; free of dye blobs, minimal base‐
line noise.
Figure  12.  Electropherogram  of  purified  products  dried  for  4  days  prior  to  elution;  presence  of  shoulders  and
messy baseline.
Figure 13. Electropherogram of purified products dried for 7 days prior to elution; extremely messy baseline and early
loss of resolution.




The gDNA used in a PCR should be as pure as possible in order to optimise the quality of
the template that will be used in downstream applications. The purity of DNA is assessed in
our laboratory using a NanoDrop ND-1000 spectrophotometer. It is important to consider
both A260/280 and A260/230 as poor DNA quality will affect downstream applications
[16,18]. An unacceptable A260/280 or A260/230 ratio indicates the presence of contaminants
in the DNA; an abnormal A260/230 indicates the presence of residual phenol or other chemi‐
cal from the extraction process, while an abnormal A260/280 most frequently indicates the
presence of protein [16,18]. If any of the ratios appear to be abnormal, DNA purification
should be considered before processing any further.
4.1.2. Dosage analysis (aCGH)
The quality requirements for gDNA used in an aCGH assay are not as stringent as those for
a sequencing assay. An awareness of the presence of significant degradation is important;
however, partial compensation for this can be made by increasing the volume of gDNA
used in the amplification and labelling step. In our laboratory, we have found that doubling
the volume of gDNA when degradation is visible on the 'check gel' (present in lanes 5-8 of
Figure 14) is an effective counter-measure. The adequacy of amplification is measured using
a NanoDrop ND-1000 spectrophotometer in order to allow the hybridisation of equimolar
amounts of test and control DNA to the array slide. A post-amplification concentration of
greater than 2500ng/µl is ideal for further processing; a sample with a post-amplification
concentration of less than 1500ng/µl is unlikely to produce good quality data for analysis.
Therefore, if there is sufficient volume of gDNA available, a repeat amplification with an in‐
creased volume of template gDNA should be undertaken.
Figure 14. Agarose gel (2%) check of gDNA quality prior to aCGH.
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4.2. Amount of DNA template used in a sequencing reaction
The DNA template  should be diluted to  2.5ng per  100bp prior  to  sequencing.  Incorrect
quantification and dilution will alter the amount of input DNA template in a sequencing
reaction, which can lead to problematic data for analysis. In our laboratory, we use Var‐
iant  ReporterTM  (Applied Biosystems Ltd)  for  automated analysis  of  sequence data.  The
signal  strength  of  the  sequence  data  is  automatically  assessed.  Data  with  good  signal
strength is above the value of 200 in the Variant ReporterTM software. Sequence data with
weak signal  strength,  a  value  below 100,  indicates  insufficient  DNA template  has  been
used in the sequencing reaction. Noisy background and a loss of sharp peak shape are al‐
so commonly evident. A repeat treatment with EXOSAP-IT and less extensive dilution of
product is necessary to avoid inaccurate analysis using sequence data with unacceptable
quality. In contrast, when excess DNA template is used in a sequencing reaction, a rapid‐
ly progressive signal loss is seen on the electropherogram. In this instance, trace quality
can be improved by diluting the eluted product with water and reloading the sample on
the capillary sequencing platform (we use an Applied Biosystems model  3130xl  Genetic
Analyzer).
4.3. CleanSEQ treatment of sequencing reactions
Agencourt  CleanSEQ is  routinely  used  to  purify  the  sequenced  products.  According  to
the manufacturer’s recommendation, 20µl of sequencing product should be cleaned with
10µl of CleanSEQ reagent.  However, we found that this leads to an excess of CleanSEQ
beads in relation to the amount of sequence product, therefore unwanted short fragments
(e.g unincorporated dNTPs and excess primers) were able to bind to beads during purifi‐
cation, and the quality of sequence data generated was consequently reduced. We found
that diluting the CleanSEQ beads 1:2 with ddH20 leads to much higher quality data.
4.4. Drying of DNA-bound beads prior to elution
This drying step is a critical QC consideration that significantly affects sequence quality.
When the purified product is dried for 24 hours prior to elution, the subsequent electro‐
pherograms are free of dye blobs,  C-shoulders and baseline noise,  and consistently pass
all QC metrics in Variant Reporter.
A drying time of 20 minutes, as suggested by manufacturer, was found to be problemat‐
ic, causing the presence of dye blobs. Dye blobs are a common artefact due to either the
presence of excess unincorporated dye or residual ethanol following product purification
[15]. Previously, operators have focused on purifying sequenced products using an accu‐
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rate  final  concentration  of  ethanol  in  an  attempt  to  achieve  consistency  of  evaporation/
drying between sequencing runs. Ethanol is highly volatile and it is therefore difficult to
achieve  consistency  -  even  the  short  period  of  time  in  which  the  vessel  containing  the
ethanol  is  open  to  allow  access  can  result  in  a  decrease  in  concentration.  Here,  we
showed that the issue of dye blobs can be resolved by simply extending the drying time
to 24 hours, allowing adequate time for all ethanol to evaporate completely, despite any
minor differences in the concentration of ethanol used.
On the other hand, we found that the quality of sequence data is adversely affected if the
drying time is extended to more than 4 days. This suggests that the stability of purified
sequencing products is another factor that affects data quality. High quality sequence da‐
ta  was obtained with a  drying time of  24  hours;  however,  the sequences were subopti‐
mal when elution and electrophoresis were carried out at day 4 or day 7 of drying. This
indicates that  purified sequencing product is  most stable for the first  24 hours and that




All sequence traces are analysed in our laboratory using Variant Reporter Software v1.0
(Applied  Biosystems).  The  current  CMGS  best  practice  guidelines  for  Sanger  sequence
analysis in diagnostic laboratories [19] recommend a PHRED score of at least 20 for bidir‐
ectional  data  (corresponding to  99% confidence  that  the  base  is  called correctly),  and a
PHRED score  of  at  least  30  for  unidirectional  data  (99.9% confidence  that  each  base  is
called correctly).  The procedure we describe above produces bidirectional sequence data
that meet our laboratory's even more stringent analysis criteria: a Variant Reporter trace
score of 35, corresponding to a false base call rate of 0.031%.
4.5.2. Dosage analysis
In order to provide simultaneous dosage analysis of all the Long QT syndrome genes, we
developed a custom designed Roche NimbleGen 12x135K CGH array. As part of the vali‐
dation of this array we analysed twenty patients with known copy number abnormalities
[20].  Analysis  of  the data  from these individuals  with known copy number changes al‐
lowed precise threshold criteria to be developed. It was determined that a log2ratio ≤-0.4
over 6 contiguous probes is indicative of a deletion, and a log2ratio of ≥0.4 over 15 con‐
tiguous probes indicative of a duplication.




It is important to monitor other QC parameters when it comes to sequence analysis of Long
QT specimens: the freshness of the Polymer (POP-7) and the usage of the capillaries in the
Applied Biosystems model 3130xl Genetic Analyzer.
Polymer (POP-7) is used to separate DNA fragments on genetic analyzers and the poly‐
mer remains stable for up to 7 days [15]. The capillary in the genetic analyzer should be
replaced after 1000 injections. Within our laboratory, we perform a regular weekly mainte‐
nance of the analyzer, and the capillary is replaced when 600 injections are reached. From
past experience, both the freshness of polymer and the usage of the capillary play a vital
role in the data quality.  Electropherograms with reduced resolution and peak shape are
produced when either  of  these  two parameters  is  suboptimal.  In  order  to  achieve  high
quality data, both freshness of polymer and usage of the capillary should be closely monitored.
5. Conclusions
We have successfully established a robust method for processing postmortem specimens for
Long QT diagnostic testing in a timely manner. The electropherograms in Figure 15 are indi‐
cative of the high quality data routinely produced, despite the limitations inherent in the
types of specimens that are referred. The blood sample used to extract gDNA for sequencing
in this example was heavily haemolysed on arrival at the laboratory.
Figure 15. High quality sequence data generated from a haemolysed blood specimen; flat baseline along with distinct
and evenly spaced peaks allow accurate basecalling.
The QC parameters described above should be monitored closely in order to consistently
achieve optimal results (Figure 16). Although the basic procedure is essentially the same as
that routinely used for sequence and aCGH analysis, the poor quality of postmortem speci‐
mens as a source of template DNA mean that particular attention needs to be paid to each
step, in particular the critical initial assessment of DNA quality, the addition of the appro‐
priate volume of template DNA to the sequencing reaction, and the drying time of the beads
used in the purification procedure prior to elution.
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Figure 16. Flowchart of potential QC problems and their solutions.
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